{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:50:40Z","timestamp":1793994640173,"version":"4.8.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9,11]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Endothelial-restricted complement activation occurs in aHUS, and clinical remission relies on efficient endothelial complement inhibition. Ex vivo serum-induced endothelial C5b-9 deposits are a sensitive tool to monitor complement activation and eculizumab effectiveness in aHUS.<\/jats:p>","DOI":"10.1182\/blood-2014-02-558296","type":"journal-article","created":{"date-parts":[[2014,7,19]],"date-time":"2014-07-19T02:36:33Z","timestamp":1405737393000},"page":"1715-1726","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":325,"title":["Dynamics of complement activation in aHUS and how to monitor eculizumab therapy"],"prefix":"10.1182","volume":"124","author":[{"given":"Marina","family":"Noris","sequence":"first","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Galbusera","sequence":"additional","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gastoldi","sequence":"additional","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Macor","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Trieste, Trieste, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Banterla","sequence":"additional","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bresin","sequence":"additional","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Tripodo","sequence":"additional","affiliation":[{"name":"Tumor Immunology Unit, Human Pathology Section, Department of Health Sciences, University of Palermo, Palermo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bettoni","sequence":"additional","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Donadelli","sequence":"additional","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Valoti","sequence":"additional","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tedesco","sequence":"additional","affiliation":[{"name":"IRCCS, Istituto Auxologico Italiano, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Amore","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplantation, Regina Margherita University Hospital, Turin, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Transplantation, Regina Margherita University Hospital, Turin, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Gotti","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"IRCCS - Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy and \u201cCentro Anna Maria Astori\u201d Science and Technology Park Kilometro Rosso, Bergamo, Italy;"},{"name":"Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2019111818400233000_B1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome.","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111818400233000_B2","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2019111818400233000_B3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"2019111818400233000_B4","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111818400233000_B5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome.","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111818400233000_B6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111818400233000_B7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2019111818400233000_B8","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1172\/JCI16651","article-title":"Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.","volume":"111","author":"Manuelian","year":"2003","journal-title":"J Clin Invest"},{"issue":"13","key":"2019111818400233000_B9","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2009-01-197640","article-title":"Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.","volume":"114","author":"Roumenina","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111818400233000_B10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1084\/jem.20070301","article-title":"Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.","volume":"204","author":"Pickering","year":"2007","journal-title":"J Exp Med"},{"issue":"1","key":"2019111818400233000_B11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical hemolytic uremic syndrome depends on complement C5.","volume":"22","author":"de Jorge","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2019111818400233000_B12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome.","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"23","key":"2019111818400233000_B13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111818400233000_B14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation.","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"2019111818400233000_B15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2019111818400233000_B16","author":"Barrow"},{"key":"2019111818400233000_B17","author":"Laurance"},{"issue":"5","key":"2019111818400233000_B18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"2019111818400233000_B19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report.","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"2019111818400233000_B20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int"},{"issue":"10","key":"2019111818400233000_B21","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1172\/JCI43343","article-title":"Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.","volume":"120","author":"Mart\u00ednez-Barricarte","year":"2010","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111818400233000_B22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20041497","article-title":"Platelet activation leads to activation and propagation of the complement system.","volume":"201","author":"Del Conde","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"2019111818400233000_B23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol"},{"key":"2019111818400233000_B24","article-title":"A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1\/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation [published online June 5, 2014].","author":"Valoti","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2019111818400233000_B25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1086\/318203","article-title":"Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.","volume":"68","author":"Richards","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"8","key":"2019111818400233000_B26","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","article-title":"Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.","volume":"26","author":"Weitz","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2019111818400233000_B27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1681\/ASN.2007080923","article-title":"The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome.","volume":"19","author":"Martinez-Barricarte","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"2019111818400233000_B28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc1308826","article-title":"Eculizumab in atypical hemolytic-uremic syndrome.","volume":"369","author":"Ring","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111818400233000_B29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molimm.2004.01.003","article-title":"Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.","volume":"41","author":"S\u00e1nchez-Corral","year":"2004","journal-title":"Mol Immunol"},{"issue":"1-2","key":"2019111818400233000_B30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.020","article-title":"Alternative complement pathway assessment in patients with atypical HUS.","volume":"365","author":"Roumenina","year":"2011","journal-title":"J Immunol Methods"},{"issue":"6","key":"2019111818400233000_B31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome.","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"issue":"16","key":"2019111818400233000_B32","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.molimm.2007.06.003","article-title":"Where next with atypical hemolytic uremic syndrome?","volume":"44","author":"Jokiranta","year":"2007","journal-title":"Mol Immunol"},{"issue":"18","key":"2019111818400233000_B33","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","article-title":"A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.","volume":"119","author":"Roumenina","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111818400233000_B34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1469-1809.2011.00671.x","article-title":"Age-related penetrance of hereditary atypical hemolytic uremic syndrome.","volume":"75","author":"Sullivan","year":"2011","journal-title":"Ann Hum Genet"},{"issue":"1","key":"2019111818400233000_B35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-1809.2009.00554.x","article-title":"Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome.","volume":"74","author":"Sullivan","year":"2010","journal-title":"Ann Hum Genet"},{"issue":"14","key":"2019111818400233000_B36","first-page":"1378","article-title":"Eculizumab in atypical hemolytic-uremic syndrome.","volume":"369","author":"Tanimoto","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111818400233000_B37","first-page":"1379","article-title":"Eculizumab in atypical hemolytic-uremic syndrome.","volume":"369","author":"Legendre","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/11\/1715\/1468410\/1715.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/11\/1715\/1468410\/1715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T23:40:30Z","timestamp":1574120430000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/11\/1715\/33019\/Dynamics-of-complement-activation-in-aHUS-and-how"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,9,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-02-558296","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,11]]}}}